Treatment Information

Back

Breast Cancer treatment details. Chemotherapy, Biologic therapy.

Centre GF Leclerc, Dijon, France.

Survival: monthsCountry:France
Toxiciy Grade:4City/State/Province:Dijon
Treatments:Chemotherapy, Biologic therapyHospital:Centre GF Leclerc
Drugs:Journal:Link
Date:Dec 2005

Description:

Patients: This Phase II study involved 33 women with HER2-over-expressing stage II or III breast cancer. The patients wished to conserve their affected breasts. The median age was 45.

Treatment: The treatment consisted of a chemotherapy agent - docetaxel and a biological therapy (monoclonal antibody)- trastuzumab.

Toxicity: Grade 1-4 toxicities included neutropenia, elevated liver enzymes, leukopenia, and alopecia.

Results: The median overall survival was not reported, but 22 patients had a complete response and seven a partial response to treatment. Twenty-three patients conserved their breasts, and the mean tumor size decreased significantly.

Support: Roche Laboratories and Sanofi-Aventis Laboratories financially supported this study, and several authors are employees of those companies. Roche manufactures and/or markets trastuzumab. Sanofi-Aventis manufactures and/or markets docetaxel.

Correspondence: Dr B. Coudert





Back